Livforsakringsbolaget Skandia Omsesidigt Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Livforsakringsbolaget Skandia Omsesidigt reduced its stake in Gilead Sciences by 1.19% during the most recent quarter end. The investment management company now holds a total of 207,137 shares of Gilead Sciences which is valued at $18,006,419 after selling 2,500 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 15, 2016.Gilead Sciences makes up approximately 0.77% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio.

Other Hedge Funds, Including , Regent Investment Management reduced its stake in GILD by selling 888 shares or 2.21% in the most recent quarter. The Hedge Fund company now holds 39,257 shares of GILD which is valued at $3,412,611. Gilead Sciences makes up approx 1.78% of Regent Investment Management’s portfolio.First Manhattan Co boosted its stake in GILD in the latest quarter, The investment management firm added 359,484 additional shares and now holds a total of 2,031,292 shares of Gilead Sciences which is valued at $176,580,214. Gilead Sciences makes up approx 1.06% of First Manhattan Co’s portfolio.Capstone Asset Management Co reduced its stake in GILD by selling 1,189 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 123,679 shares of GILD which is valued at $10,605,474. Gilead Sciences makes up approx 0.31% of Capstone Asset Management Co’s portfolio.Stokes Hubbell Capital Management reduced its stake in GILD by selling 311 shares or 10.31% in the most recent quarter. The Hedge Fund company now holds 2,706 shares of GILD which is valued at $234,204. Gilead Sciences makes up approx 0.10% of Stokes Hubbell Capital Management’s portfolio.

Gilead Sciences opened for trading at $86.94 and hit $87.34 on the upside on Monday, eventually ending the session at $86.93, with a gain of 0.30% or 0.26 points. The heightened volatility saw the trading volume jump to 67,88,252 shares. Company has a market cap of $115,775 M.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.